Correction to: Purinergic Signalling (2011) 7:489–497
Due to the authors’ carelessness, we used mistakenly PBMCs isolated from same patient in Fig. 1a for P2X3 immunoreactivity in VI: PUE-treated group on the second day (Third row middle graph) and VII: PUE-treated on the third day (Third row right- side graph).
Fig. 1 Effect of puerarin on the expression of P2X3 receptors in peripheral blood mononuclear cells (PBMCs) by immunohistochemistry. a I: healthy volunteers (control); II: normal saline (NS)-treated group on the first day; III: NS-treated group on the second day; IV: NS-treated group on the third day; V: puerarin (PUE)-treated group on the first day; VI: PUE-treated group on the second day; VII: PUE-treated on the third day. (Arrows indicate the immunostaining of PBMCs; scale bars, 20 μm)
Original Fig. 1a
The photo of P2X3 immunoreactivity in VII: PUE-treated on the third day (Third row right- side graph) are replaced.
Corrected 1a
Finally, we regret the errors on our part, as we did not catch the mistake during editing, and apologize for any confusion this may cause.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Xin Li, Jun Zhang, Yun Gao, and Yang Yang are jointly first authors.
The online version of the original article can be found at https://doi.org/10.1007/s11302-011-9248-5
Rights and permissions
About this article
Cite this article
Li, X., Zhang, J., Gao, Y. et al. Correction to: Puerarin alleviates burn-related procedural pain mediated by P2X3 receptors. Purinergic Signalling 16, 601–602 (2020). https://doi.org/10.1007/s11302-020-09739-6
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11302-020-09739-6